Novel Targets for the Pathogenesis of Pancreatic Cancer

Dear Colleagues,

Pancreatic cancer is a lethal malignancy with limited therapeutic options for long-term survival. It is the fourth leading cause of cancer-related death and represents 7% of all cancers. In 2020, it was estimated that 57,600 new cases were diagnosed in the USA. Pancreatic cancer develops through non-invasive epithelial proliferation of pancreatic ducts and mutation of driver genes KRAS, CDKN2A, TP53, and SMAD4. It is difficult to diagnose at an early stage, and there are currently no validated and specific screening tests available. Surgical resection and adjuvant chemotherapy with gemcitabine are only an option in the later stages of the disease. Combination therapy or polytherapy, which uses two or more therapeutic agents to treat cancer patients, is more popular. This type of therapy targets key pathways in a synergistic or additive manner compared to the monotherapy approach. It is, however, important to use FDA-approved repurposed pharmaceutical agents in this combination therapy, which may be beneficial for patients in terms of financial burden. This Special Issue focuses on exploring the therapeutic and potential targets in pancreatic cancer. We invite articles related to all aspects of pancreatic cancer pathogenesis and treatment. There are no specifications or limitations on the type of studies used in pancreatic cancer.

Dr. Palanisamy Nallasamy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pancreatic cancer
• combination therapy
• gemcitabine